Plasma apelin levels in diabetic patients with and without neuropathy

• Authors: Mehmet Şenol , Hakan Terekeci , Osman İpçioğlu , Eylem Çağıltay , Erdem Toğrol , Fatih Özdağ , Burak Şahan , Çağatay Öktenli , Mehmet Saraçoğlu
• Languages of publication: EN

Abstracts

EN

The aim of this study was to investigate the plasma apelin levels in diabetic patients with and without neuropathy. All consecutive diabetic patients who presented for routine follow-up at our outpatient clinic were invited to participate in this clinical study. Forty diabetic patients (20 female and 20 male) and twenty-two non-diabetic control subjects (9 female and 13 male) were included in the study. Neurological evaluations in diabetic subjects were done by nerve conduction studies and evaluated with the Neuropathy Symptom Score. Fasting plasma glucose, HbA1c, lipid and apelin levels were measured in each subject. The mean plasma apelin level was significantly higher in the diabetic patients than in the control subjects (p = 0.026). Apelin levels were statistically similar between diabetic patients with and without neuropathy (p = 0.43). Further, plasma apelin levels were found to be higher in diabetic patients with neuropathy when compared with those of healthy control subjects (p = 0.02). In diabetic patients with neuropathy, plasma apelin levels correlated significantly with diabetes duration (r = 0.5, p = 0.02). We propose that apelin levels in diabetic patients are higher in the presence of neuropathy and longer disease duration, although this might not solely suffice as an indicator for the presence of neuropathy in diabetic patients. Drawing attention to the possible association between the apelinergic system and diabetes mellitus, we believe that further studies with larger samples should be carried out also to investigate the presence of retinopathy and nephropathy.

Keywords

EN

Apelin; Diabetic neuropathy; Metabolic control; Neuropathy symptom score

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2009
• Volume: 4
• Issue: 2
• Pages: 241-244

Dates

published

1 - 6 - 2009

online

27 - 3 - 2009

Contributors

author

Mehmet Şenol

• Department of Neurology, Gülhane Military Medical Academy Haydarpaşa Training Hospital, 34668, Istanbul, Turkey

author

Hakan Terekeci

• Department of Internal Medicine, Gülhane Military Medical Academy Haydarpaşa Training Hospital, 34668, Istanbul, Turkey

author

Osman İpçioğlu

• Department of Biochemistry, Gülhane Military Medical Academy Haydarpaşa Training Hospital, 34668, Istanbul, Turkey

author

Eylem Çağıltay

• Department of Internal Medicine, Gülhane Military Medical Academy Haydarpaşa Training Hospital, 34668, Istanbul, Turkey

author

Erdem Toğrol

• Department of Neurology, Gülhane Military Medical Academy Haydarpaşa Training Hospital, 34668, Istanbul, Turkey

author

Fatih Özdağ

• Department of Neurology, Gülhane Military Medical Academy Haydarpaşa Training Hospital, 34668, Istanbul, Turkey

author

Burak Şahan

• Department of Internal Medicine, Gülhane Military Medical Academy Haydarpaşa Training Hospital, 34668, Istanbul, Turkey

author

Çağatay Öktenli

• Department of Internal Medicine, Gülhane Military Medical Academy Haydarpaşa Training Hospital, 34668, Istanbul, Turkey

author

Mehmet Saraçoğlu

• Department of Neurology, Gülhane Military Medical Academy Haydarpaşa Training Hospital, 34668, Istanbul, Turkey

References

• [1] Lee D.K., George S.R., O’Dowd B.F., Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity, Trends Pharmacol. Sci., 2006, 27, 190–194 http://dx.doi.org/10.1016/j.tips.2006.02.006[Crossref]
• [2] Kleinz M.J., Davenport A.P., Emerging roles of apelin in biology and medicine, Pharmacol. Ther., 2005, 107, 198–211 http://dx.doi.org/10.1016/j.pharmthera.2005.04.001[Crossref]
• [3] Erdem G., Dogru T., Tasci I., Sonmez A., Tapan S., Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus, Exp. Clin. Endocrinol. Diabetes., 2008, 116, 289–292 http://dx.doi.org/10.1055/s-2007-1004564
• [4] Matthews D.R., Hosker J.P., Turner R.C., Homeostasis Model Assesment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 1985, 28, 412–419 http://dx.doi.org/10.1007/BF00280883[Crossref]
• [5] Dyck P.J., Detection, characterization and staging of polyneuropathy: assessed in diabetics, Muscle. Nerve., 1998, 11, 21–32 http://dx.doi.org/10.1002/mus.880110106[Crossref]
• [6] Bełtowski J., Apelin and visfatin: Unique “beneficial” adipokines upregulated in obesity? Med. Sci. Monit., 2006, 12, 112–119
• [7] Ladeiras-Lopes R., Ferreira-Martins J., Leite-Moreira A.F., The Apelinergic System: The Role Played in Human Physiology and Pathology and Potential Therapeutic Applications. Arq. Bras. Cardiol., 2008, 90, 343–349 http://dx.doi.org/10.1590/S0066-782X2008000500012[Crossref]
• [8] Boucher J., Masri B., Daviaud D., Gesta S., Guignö C., Mazzucotelli A., et al., Apelin, a newly identified adipokine up-regulated by insulin and obesity, Endocrinology, 2005, 146, 1764–1771 http://dx.doi.org/10.1210/en.2004-1427[Crossref]
• [9] Li L., Yang G., Li Q., Tang Y., Yang M., Yang H., Li K., Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects, Exp. Clin. Endocrinol. Diabetes., 2006, 114, 544–548 http://dx.doi.org/10.1055/s-2006-948309

Identifiers

DOI

10.2478/s11536-008-0075-1